Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) CEO Philip Young spoke to Proactive about the development of its initial Phase 1 study plan to demonstrate the safety and appropriate dosing range for its proprietary new chemical entity L-130, a unique synthetic analogue of the psychedelic psilocin, to treat neurologic disorders.
Young told Proactive that both chemical entities are unique synthetic analogues of psilocin, the active metabolite of natural psilocybin which is a substance extracted from a species of psychedelic mushroom.
The initial focus for the clinical program is to treat neurologic disorders, such as severe anxiety. Young said the company is in the final stages of selecting a contract research organization to support these studies.